Mary Kruczynski

Articles by Mary Kruczynski

Oral Oncolytics: Part 2-Legislation Targeting Cost & Access, and Other Initiatives to Reduce Costs

ByRobert Mancini, PharmD, BCOP,Ali Mcbride, PharmD, MS,Mary Kruczynski

September 15th 2013

We examine efforts to correct cost inequities of oral anti-cancer agents through legislation, and we look at further efforts to reduce the cost of oral chemotherapy via cycle management and waste reduction.

Oral Oncolytics: Part 1-Financial, Adherence, and Management Challenges

ByRobert Mancini, PharmD, BCOP,Ali Mcbride, PharmD, MS,Mary Kruczynski

August 15th 2013

The management of patients receiving treatment with oral oncolytics presents challenges such as cost, adherence, monitoring of side effects, and safe handling.

Latest Updated Articles

Oral Oncolytics: Part 1-Financial, Adherence, and Management Challenges
August 15th 2013
Oral Oncolytics: Part 2-Legislation Targeting Cost & Access, and Other Initiatives to Reduce Costs
September 15th 2013

Trending on CancerNetwork

FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy

FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer

Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer

TIP125 ReDiscover-2, a Phase 3 Study of Zovegalisib (RLY-2608) + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-Mutant HR+/ HER2- Breast Cancer Following Recurrence or Progression on or After Treatment With a CDK4/6 Inhibitor (Trial in Progress)